focus -WSS

focus

author：explore 2025-09-30 20:37:28 - browse：176

Enticed by the immense market opened by GLP-1 weight loss drugs Wegovy and Zepbound, a handful of biotech companies are trying to develop next-generation, longer-lasting therapies based on a very different approach: RNA interference.

This Nobel Prize-winning science works by degrading the biological blueprints that RNA use to make proteins — without the genetic instructions, the troublesome proteins are never made and the gene is essentially muted.

If the companies succeed, it would be a significant shift in the obesity treatment revolution, away from weekly drugs targeting hormones to medications that could be given much less frequently — twice a year or even less — and pinpoint genetic contributors to weight.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Vertex cell therapy lets patients with type 1 diabetes stop insulin

WSS

Fetal surgery at risk from Dobbs and new abortion restrictions

Archived: an online chat discussing Ebola, vaccines, and a new epidemic

Trump’s hydroxychloroquine hype: a risk to my treatment and to him

Crowdfunding for unproven stem cell procedures spreads misinformation

Cigna, Humana reportedly in talks to merge

How to pay for weight loss drugs and save Medicare

hotspot

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

Peter Hotez and the public health issue of online harassment

Skip the lead apron during X

Continuity nursing helped my family in our darkest PICU moments

Will the market for weight loss drugs really reach $100 billion?

Affirmative action in medical school literally saved lives

What to do when lifesaving products contribute to climate change

After affirmative action ruling, medical educators look to 'holistic review'

Fetal surgery at risk from Dobbs and new abortion restrictions

Continuity nursing helped my family in our darkest PICU moments

Canadians with cystic fibrosis outlive Americans by a decade

focus

What to do when lifesaving products contribute to climate change

With clinical trial data readouts, here's how to spot spin

FDA investigates CAR

UnitedHealth’s Optum accused of antitrust violations in California

Canadians with cystic fibrosis outlive Americans by a decade

What don’t we know about an Alzheimer’s drug side effect?

focus

knowledge

knowledge

leisure time